Alpha-interferon for relapsed non-Hodgkin's lymphoma.

摘要

The long-term survival for patients with non-Hodgkin's lymphoma who have undergone autologous hematopoietic stem cell transplantation and subsequently relapsed has been poor. In a study by Vaishampayan et al.,1 patients who relapsed after autologous bone marrow transplantation had a 3-year survival rate of 55% if they responded to further salvage therapy, whereas patients who did not respond had a 3-year survival of 14%. Vose et al? found that patients with Hodgkin's disease who relapsed after an autologous transplant had a better median survival (i.e. 10.5 months) than patients with relapsed non-Hodgkin's lymphoma (i.e. 3 months).